Marathon Petroleum Corp vs Zimmer Biomet Holdings Inc — how do they compare? Marathon Petroleum Corp trades at $333.33 (market cap $94.48B), while Zimmer Biomet Holdings Inc trades at $94.99 (market cap $18.55B). The key difference: Marathon Petroleum Corp is far larger — about 5.1× Zimmer Biomet Holdings Inc's market cap, and Marathon Petroleum Corp pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| MPC | ZBH | |
|---|---|---|
Market Cap | $94.48B | $18.55B |
Sector | Energy | Health |
52-Week High | $336.42 | $107.71 |
52-Week Low | $159.11 | $79.58 |
Enterprise Value | $121.00B | $25.61B |
Dividend Yield | 1.19% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $320.32, up 7.42% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations by 22.1%. The stock is in a bullish technical trend, supported by robust refining margins and disciplined operations. Recent news highlights MPC's advantage from global refining tightness and geopolitical disruptions. Valuation ratios like P/E of 11.67 and P/S of 0.65 suggest potential undervaluation relative to earnings growth.
Outlook remains positive with analyst consensus at Buy (75.76%) and a $332.70 price target, though risks include volatile energy markets and debt levels. Earnings growth and cash returns via dividends and buybacks are key catalysts, but investors should monitor refining margin sustainability and macroeconomic pressures.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Latest headlines on both assets
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →